StockNews.com initiated coverage on shares of Inuvo (NYSE:INUV – Get Free Report) in a report issued on Wednesday. The firm set a “hold” rating on the stock.
Separately, LADENBURG THALM/SH SH initiated coverage on Inuvo in a research note on Tuesday, April 2nd. They set a “buy” rating and a $1.00 target price for the company.
Check Out Our Latest Report on Inuvo
Inuvo Price Performance
Inuvo (NYSE:INUV – Get Free Report) last issued its earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share for the quarter. The company had revenue of $20.84 million during the quarter. Inuvo had a negative return on equity of 56.15% and a negative net margin of 14.06%. Research analysts anticipate that Inuvo will post 0.01 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Inuvo stock. Procyon Advisors LLC raised its position in shares of Inuvo, Inc. (NYSE:INUV – Free Report) by 121.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 61,600 shares of the company’s stock after purchasing an additional 33,827 shares during the quarter. Procyon Advisors LLC’s holdings in Inuvo were worth $26,000 as of its most recent SEC filing. 29.36% of the stock is currently owned by institutional investors and hedge funds.
About Inuvo
Inuvo, Inc engages in the advertising technology and services business primarily in the United States. It sells information technology solutions to brands, agencies, and large consolidators of advertising demand (platforms). Its platforms optimize the purchase and placement of advertising in real time.
Featured Articles
- Five stocks we like better than Inuvo
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Garmin Navigates to New Highs Driven By Wearables Trend
- Why Invest in Biotech Stocks
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Want to Profit on the Downtrend? Downtrends, Explained.
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Inuvo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inuvo and related companies with MarketBeat.com's FREE daily email newsletter.